284 related articles for article (PubMed ID: 14638501)
1. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.
Hayden FG; Turner RB; Gwaltney JM; Chi-Burris K; Gersten M; Hsyu P; Patick AK; Smith GJ; Zalman LS
Antimicrob Agents Chemother; 2003 Dec; 47(12):3907-16. PubMed ID: 14638501
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers.
Hsyu PH; Pithavala YK; Gersten M; Penning CA; Kerr BM
Antimicrob Agents Chemother; 2002 Feb; 46(2):392-7. PubMed ID: 11796347
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.
Eccles R; Winther B; Johnston SL; Robinson P; Trampisch M; Koelsch S
Respir Res; 2015 Oct; 16():121. PubMed ID: 26438038
[TBL] [Abstract][Full Text] [Related]
4. Effects of dietary supplementation with conjugated linoleic acid on experimental human rhinovirus infection and illness.
Peterson KM; O'Shea M; Stam W; Mohede IC; Patrie JT; Hayden FG
Antivir Ther; 2009; 14(1):33-43. PubMed ID: 19320235
[TBL] [Abstract][Full Text] [Related]
5. Intranasal pirodavir (R77,975) treatment of rhinovirus colds.
Hayden FG; Hipskind GJ; Woerner DH; Eisen GF; Janssens M; Janssen PA; Andries K
Antimicrob Agents Chemother; 1995 Feb; 39(2):290-4. PubMed ID: 7726484
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial.
Turner RB; Wecker MT; Pohl G; Witek TJ; McNally E; St George R; Winther B; Hayden FG
JAMA; 1999 May; 281(19):1797-804. PubMed ID: 10340366
[TBL] [Abstract][Full Text] [Related]
7. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.
Hayden FG; Albrecht JK; Kaiser DL; Gwaltney JM
N Engl J Med; 1986 Jan; 314(2):71-5. PubMed ID: 3001519
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of intranasal ipratropium bromide in common colds. A randomized, double-blind, placebo-controlled trial.
Hayden FG; Diamond L; Wood PB; Korts DC; Wecker MT
Ann Intern Med; 1996 Jul; 125(2):89-97. PubMed ID: 8678385
[TBL] [Abstract][Full Text] [Related]
9. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.
Farr BM; Gwaltney JM; Adams KF; Hayden FG
Antimicrob Agents Chemother; 1984 Jul; 26(1):31-4. PubMed ID: 6089652
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection.
Hayden FG; Gwaltney JM
Antimicrob Agents Chemother; 1982 Jun; 21(6):892-7. PubMed ID: 6287928
[TBL] [Abstract][Full Text] [Related]
11. Modification of experimental rhinovirus colds by receptor blockade.
Hayden FG; Gwaltney JM; Colonno RJ
Antiviral Res; 1988 Jul; 9(4):233-47. PubMed ID: 2849376
[TBL] [Abstract][Full Text] [Related]
12. Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study.
Lindberg BF; Nelson I; Ranstam J; Riker DK
PLoS One; 2023; 18(1):e0279204. PubMed ID: 36652464
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial.
Ludwig M; Enzenhofer E; Schneider S; Rauch M; Bodenteich A; Neumann K; Prieschl-Grassauer E; Grassauer A; Lion T; Mueller CA
Respir Res; 2013 Nov; 14(1):124. PubMed ID: 24219370
[TBL] [Abstract][Full Text] [Related]
14. Topical enviroxime against rhinovirus infection.
Levandowski RA; Pachucki CT; Rubenis M; Jackson GG
Antimicrob Agents Chemother; 1982 Dec; 22(6):1004-7. PubMed ID: 6297380
[TBL] [Abstract][Full Text] [Related]
15. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837).
al-Nakib W; Higgins PG; Barrow GI; Tyrrell DA; Andries K; Vanden Bussche G; Taylor N; Janssen PA
Antimicrob Agents Chemother; 1989 Apr; 33(4):522-5. PubMed ID: 2543283
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges.
Al-Nakib W; Higgins PG; Barrow I; Batstone G; Tyrrell DA
J Antimicrob Chemother; 1987 Dec; 20(6):893-901. PubMed ID: 3440773
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection.
Hayden FG; Andries K; Janssen PA
Antimicrob Agents Chemother; 1992 Apr; 36(4):727-32. PubMed ID: 1503435
[TBL] [Abstract][Full Text] [Related]
18. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.
Hayden FG; Kaiser DL; Albrecht JK
Antimicrob Agents Chemother; 1988 Feb; 32(2):224-30. PubMed ID: 2834996
[TBL] [Abstract][Full Text] [Related]
19. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds.
Hayden FG; Gwaltney JM
J Infect Dis; 1984 Aug; 150(2):174-80. PubMed ID: 6381610
[TBL] [Abstract][Full Text] [Related]
20. Ipratropium bromide treatment of experimental rhinovirus infection.
Gaffey MJ; Hayden FG; Boyd JC; Gwaltney JM
Antimicrob Agents Chemother; 1988 Nov; 32(11):1644-7. PubMed ID: 2855297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
